Big pharma blockbusters are gong off patent within the next few years and sales revenue will be transfered to generic houses. The beneficiaries of a very profitable period of patent exclusivity will be the top and up and coming generic houses. In my view MYL is a sleeper that is ready to be discovered and will reap big rewards. COmpany history shows excellent track record. Early success and sustained growth together with changing market conditions and opportunity likely signals this one as a winner. THis may be a long term buy and hold opportunity. 3-5 years.
$14.69 (01/21/08)
